Identification

Name
Tazarotene
Accession Number
DB00799
Description

Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids. It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage).

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 351.462
Monoisotopic: 351.129299611
Chemical Formula
C21H21NO2S
Synonyms
  • Tazarotene
  • Tazarotène
  • Tazaroteno
  • Tazarotenum
External IDs
  • AGN 190168
  • AGN-190168

Pharmacology

Indication

Used to treat psoriasis, acne and sun damaged skin (photodamage).

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Following topical application, tazarotene undergoes esterase hydrolysis to form its active metabolite, tazarotenic acid. When treating acne tazarotene may be taken in conjunction with an oral antibiotic. Tazarotene has been shown in peer-reviewed double blinded studies to reduce: mottling and hyperpigmentation, sallowness, fine wrinkling and coarse wrinkling in sun damaged skin. Histological studies have shown that long term (greater than 1 year) use of Tazarotene is associated with a significant reduction in atypical melanocytes and keratocytes - cells considered to be precursors of skin cancer. Some studies have shown long term use of Tazarotene to be associated with increased collagen production and better organization of skin collagen bundles.

Mechanism of action

Although the exact mechanism of tazarotene action is not known, studies have shown that the active form of the drug (tazarotenic acid) binds to all three members of the retinoic acid receptor (RAR) family: RARa, RARb, and RARg, but shows relative selectivity for RARb, and RARg and may modify gene expression. It also has affinity for RXR receptors.

TargetActionsOrganism
ARetinoic acid receptor alpha
agonist
Humans
ARetinoic acid receptor RXR-beta
agonist
Humans
ARetinoic acid receptor gamma
agonist
Humans
ARetinoic acid receptor beta
agonist
Humans
Absorption

Minimal systemic absorption of tazarotene occurs due to its rapid metabolism in the skin to the active metabolite, tazarotenic acid, which can be systemically absorbed and further metabolized. Gender had no influence on the systemic bioavailability of tazarotenic acid.

Volume of distribution
Not Available
Protein binding

The active form of the drug, tazarotenic acid, is highly bound to plasma proteins (>99%).

Metabolism

Undergoes esterase hydrolysis in skin to form its active metabolite, tazarotenic acid. Tazarotenic acid is further metabolized in skin and, after systemic absorption, hepatically metabolized to sulfoxides, sulfones, and other polar products for elimination.

Hover over products below to view reaction partners

Route of elimination

Tazarotene and tazarotenic acid were metabolized to sulfoxides, sulfones and other polar metabolites which were eliminated through urinary and fecal pathways.

Half-life

The half-life of the active form of the drug, tazarotenic acid, is approximately 18 hours in normal and psoriatic patients.

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Excessive topical use may lead to marked redness, peeling, or discomfort. Oral ingestion of the drug may affect liver function causing hypertriglyceridemia. Other symptoms may include conjunctival irritation, hair loss, headache, edema, fatigue, dermatitis, nausea, and visual disturbances. Oral administration of this material to rats and rabbits at doses of 0.20 mg/kg/day (rabbits) and 0.25 mg/kg/day (rats) resulted in developmental toxicity. A no effect level of 0.05 mg/kg/day was established. Similar teratogenic effects have been reported for other retinoid compounds.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe metabolism of Tazarotene can be increased when combined with Abatacept.
AbirateroneThe metabolism of Tazarotene can be decreased when combined with Abiraterone.
AdalimumabThe metabolism of Tazarotene can be increased when combined with Adalimumab.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Tazarotene.
AlpelisibThe metabolism of Tazarotene can be decreased when combined with Alpelisib.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Tazarotene.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Tazarotene.
AmitriptylineThe metabolism of Tazarotene can be decreased when combined with Amitriptyline.
AmodiaquineThe metabolism of Tazarotene can be decreased when combined with Amodiaquine.
AnakinraThe metabolism of Tazarotene can be increased when combined with Anakinra.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

International/Other Brands
Zorac
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ArazloLotion0.45 mg/1gTopicalBausch Health US LLC2019-12-19Not applicableUS flag
AvageCream1 mg/1gCutaneousAllergan, Inc.2003-01-072020-06-18US flag
FabiorAerosol, foam1 mg/1gTopicalStiefel Laboratories, Inc.2013-09-042018-09-30US flag
FabiorAerosol, foam1 mg/1gTopicalMayne Pharma2017-03-10Not applicableUS flag
TazaroteneCream0.5 mg/1gTopicalPacific Pharma, Inc.2017-04-15Not applicableUS flag
TazaroteneCream1 mg/1gTopicalPacific Pharma, Inc.2017-04-15Not applicableUS flag
TazoracGel0.1 %TopicalAllergan1997-04-10Not applicableCanada flag
TazoracCream0.05 %TopicalAllergan2001-08-31Not applicableCanada flag
TazoracGel1 mg/1gCutaneousAllergan, Inc.1997-08-01Not applicableUS flag
TazoracGel1 mg/1gCutaneousAlmirall, LLC2020-02-21Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
TazaroteneCream1 mg/1gTopicalFougera Pharmaceuticals Inc.2019-01-28Not applicableUS flag
TazaroteneCream1 mg/1gTopicalCosette Pharmaceuticals, Inc.2020-08-24Not applicableUS flag
TazaroteneCream1 mg/1gTopicalTaro Pharmaceuticals U.S.A., Inc.2017-04-03Not applicableUS flag
TazaroteneCream1 mg/1gTopicalCosette Pharmaceuticals, Inc.2017-12-22Not applicableUS flag
TazaroteneCream1 mg/1gTopicalTaro Pharmaceuticals U.S.A., Inc.2017-04-03Not applicableUS flag
Tazarotene CreamCream1 mg/1gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2019-01-28Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
DuobriiTazarotene (0.045 %) + Ulobetasol propionate (0.01 %)LotionTopicalBausch Health, Canada Inc.2020-08-04Not applicableCanada flag
DuobriiTazarotene (0.45 mg/1g) + Ulobetasol propionate (0.1 mg/1g)LotionTopicalBausch Health US, LLC2019-04-25Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
011312 Niacinamide 4% / Tazarotene 0.05%Tazarotene (0.05 g/100g) + Nicotinamide (4 g/100g)CreamTopicalSincerus Florida, LLC2020-07-02Not applicableUS flag
Clindamycin 1% / Niacinamide 2% / Tazarotene 0.05%Tazarotene (0.05 g/100g) + Clindamycin phosphate (1 g/100g) + Nicotinamide (2 g/100g)GelTopicalSincerus Florida, LLC2019-05-10Not applicableUS flag
Hyaluronic Acid Sodium Salt 0.5% / Tazarotene 0.05%Tazarotene (0.05 g/100g) + Sodium hyaluronate (0.5 g/100g)CreamTopicalSincerus Florida, LLC2019-05-10Not applicableUS flag
Hyaluronic Acid Sodium Salt 0.5% / Tazarotene 0.1%Tazarotene (0.1 g/100g) + Sodium hyaluronate (0.5 g/100g)CreamTopicalSincerus Florida, LLC2019-05-07Not applicableUS flag
Niacinamide 4% / Tazarotene 0.05%Tazarotene (0.05 g/100g) + Nicotinamide (4 g/100g)CreamTopicalSincerus Florida, LLC2019-05-01Not applicableUS flag
Niacinamide 4% / Tazarotene 0.1%Tazarotene (0.1 g/100g) + Nicotinamide (4 g/100g)CreamTopicalSincerus Florida, LLC2019-05-01Not applicableUS flag
Niacinamide 4% / Tazarotene 0.1%Tazarotene (0.1 g/100g) + Nicotinamide (4 g/100g)GelTopicalSincerus Florida, LLC2019-05-10Not applicableUS flag

Categories

ATC Codes
D05AX05 — Tazarotene
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as retinoids. These are oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Retinoids
Direct Parent
Retinoids
Alternative Parents
Thiochromanes / Pyridinecarboxylic acids / 1-benzothiopyrans / Alkylarylthioethers / Thiopyrans / Benzenoids / Heteroaromatic compounds / Carboxylic acid esters / Monocarboxylic acids and derivatives / Azacyclic compounds
show 5 more
Substituents
1-benzothiopyran / Alkylarylthioether / Aromatic heteropolycyclic compound / Aryl thioether / Azacycle / Benzenoid / Benzothiopyran / Carboxylic acid derivative / Carboxylic acid ester / Heteroaromatic compound
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
ethyl ester, retinoid, pyridines, acetylenic compound, thiochromane (CHEBI:32184)

Chemical Identifiers

UNII
81BDR9Y8PS
CAS number
118292-40-3
InChI Key
OGQICQVSFDPSEI-UHFFFAOYSA-N
InChI
InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3
IUPAC Name
ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate
SMILES
CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1

References

Synthesis Reference

Samuele Frigoli, Claudio Fuganti, Stefano Serra, Francesco Pizzocaro, Angelo Bedeschi, Paolo Tubertini, "Process for the preparation of Tazarotene." U.S. Patent US20060205950, issued September 14, 2006.

US20060205950
General References
Not Available
Human Metabolome Database
HMDB0014937
KEGG Drug
D01132
KEGG Compound
C12531
PubChem Compound
5381
PubChem Substance
46508992
ChemSpider
5188
BindingDB
50265951
RxNav
83947
ChEBI
32184
ChEMBL
CHEMBL1657
ZINC
ZINC000001542199
Therapeutic Targets Database
DAP000462
PharmGKB
PA164746821
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Tazarotene
AHFS Codes
  • 84:92.00 — Misc. Skin and Mucous Membrane Agents
FDA label
Download (90.3 KB)
MSDS
Download (25.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentAcne Vulgaris4
4CompletedTreatmentBrittle Nails1
4RecruitingTreatmentPsoriasis1
4TerminatedTreatmentAcne Vulgaris1
3CompletedTreatmentAcne Vulgaris7
3CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)2
3RecruitingTreatmentPsoriasis Vulgaris (Plaque Psoriasis)2
2CompletedTreatmentAcne Vulgaris5
2CompletedTreatmentNail Psoriasis1
2CompletedTreatmentNeoplastic Syndrome1

Pharmacoeconomics

Manufacturers
  • Allergan inc
Packagers
  • Allergan Inc.
  • Physicians Total Care Inc.
Dosage Forms
FormRouteStrength
LotionTopical0.45 mg/1g
LotionTopical
Aerosol, foamTopical1 mg/1g
CreamTopical
GelTopical
Gel0.05 %
CreamTopical0.5 mg/1g
CreamTopical1 mg/1g
GelTopical0.1 g
GelTopical0.05 g
CreamCutaneous0.05 mg/1g
CreamCutaneous0.1 mg/1g
CreamCutaneous0.5 mg/1g
CreamCutaneous1 mg/1g
CreamTopical0.05 %
CreamTopical0.1 %
GelCutaneous0.5 mg/1g
GelCutaneous1 mg/1g
GelOral1 mg/1g
GelTopical0.05 %
GelTopical0.1 %
Gel0.1 %
Cream0.1 %
Prices
Unit descriptionCostUnit
Tazorac 0.1% Gel 100 gm Tube638.75USD tube
Tazorac 0.05% Gel 100 gm Tube601.14USD tube
Tazorac 60 gm Tube .1% 60 gm Tube383.22USD tube
Tazorac 60 gm Tube .05% 60 gm Tube360.72USD tube
Tazorac 0.1% Gel 30 gm Tube191.64USD tube
Tazorac 30 gm Tube .1% 30 gm Tube191.64USD tube
Tazorac 0.05% Cream 30 gm Tube180.39USD tube
Tazorac 0.05% Gel 30 gm Tube180.39USD tube
Tazorac 0.1% cream5.59USD g
Tazorac 0.05% cream5.26USD g
Tazorac 0.05 % Gel1.49USD g
Tazorac 0.1 % Gel1.49USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5914334No1999-06-222014-06-07US flag
US5089509No1992-02-182011-06-13US flag
CA2191773No2004-08-102015-08-10Canada flag
US8808716No2014-08-192030-02-24US flag
US8809307No2014-08-192031-11-02US flag
US6517847No2003-02-112020-08-03US flag
US10251895No2019-04-092036-06-06US flag
US10478502No2019-11-192031-11-02US flag
US10426787No2019-10-012036-06-06US flag
US10568859No2010-02-242030-02-24US flag
US10688071No2010-02-242030-02-24US flag
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
logP5.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00075 mg/mLALOGPS
logP5.15ALOGPS
logP5.22ChemAxon
logS-5.7ALOGPS
pKa (Strongest Basic)1.23ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area39.19 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity97.88 m3·mol-1ChemAxon
Polarizability40.31 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9936
Blood Brain Barrier+0.9675
Caco-2 permeable+0.5233
P-glycoprotein substrateSubstrate0.5758
P-glycoprotein inhibitor IInhibitor0.5422
P-glycoprotein inhibitor IINon-inhibitor0.5926
Renal organic cation transporterNon-inhibitor0.8219
CYP450 2C9 substrateNon-substrate0.7308
CYP450 2D6 substrateNon-substrate0.7687
CYP450 3A4 substrateSubstrate0.5187
CYP450 1A2 substrateInhibitor0.6172
CYP450 2C9 inhibitorInhibitor0.6385
CYP450 2D6 inhibitorNon-inhibitor0.8531
CYP450 2C19 inhibitorInhibitor0.6586
CYP450 3A4 inhibitorNon-inhibitor0.6387
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6124
Ames testNon AMES toxic0.8154
CarcinogenicityNon-carcinogens0.8925
BiodegradationNot ready biodegradable0.9946
Rat acute toxicity2.5435 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9968
hERG inhibition (predictor II)Non-inhibitor0.7757
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0uk9-0129000000-2db71aa7cf68c539db6d

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RARA
Uniprot ID
P10276
Uniprot Name
Retinoic acid receptor alpha
Molecular Weight
50770.805 Da
References
  1. Baumann L, Vujevich J, Halem M, Martin LK, Kerdel F, Lazarus M, Pacheco H, Black L, Bryde J: Open-label pilot study of alitretinoin gel 0.1% in the treatment of photoaging. Cutis. 2005 Jul;76(1):69-73. [PubMed:16144296]
  2. Chandraratna RA: Tazarotene--first of a new generation of receptor-selective retinoids. Br J Dermatol. 1996 Oct;135 Suppl 49:18-25. [PubMed:9035701]
  3. Yen A, Fenning R, Chandraratna R, Walker P, Varvayanis S: A retinoic acid receptor beta/gamma-selective prodrug (tazarotene) plus a retinoid X receptor ligand induces extracellular signal-regulated kinase activation, retinoblastoma hypophosphorylation, G0 arrest, and cell differentiation. Mol Pharmacol. 2004 Dec;66(6):1727-37. Epub 2004 Sep 21. [PubMed:15383624]
  4. Meder W, Wendland M, Busmann A, Kutzleb C, Spodsberg N, John H, Richter R, Schleuder D, Meyer M, Forssmann WG: Characterization of human circulating TIG2 as a ligand for the orphan receptor ChemR23. FEBS Lett. 2003 Dec 18;555(3):495-9. [PubMed:14675762]
  5. Wang Q, Lee D, Sysounthone V, Chandraratna RAS, Christakos S, Korah R, Wieder R: 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res Treat. 2001 May;67(2):157-68. [PubMed:11519864]
  6. Nagpal S, Chandraratna RA: Recent developments in receptor-selective retinoids. Curr Pharm Des. 2000 Jun;6(9):919-31. [PubMed:10828316]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RXRB
Uniprot ID
P28702
Uniprot Name
Retinoic acid receptor RXR-beta
Molecular Weight
56921.38 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Nagpal S, Chandraratna RA: Recent developments in receptor-selective retinoids. Curr Pharm Des. 2000 Jun;6(9):919-31. [PubMed:10828316]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RARG
Uniprot ID
P13631
Uniprot Name
Retinoic acid receptor gamma
Molecular Weight
50341.405 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  4. Arechalde A, Saurat JH: Management of psoriasis: the position of retinoid drugs. BioDrugs. 2000 May;13(5):327-33. [PubMed:18034539]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RARB
Uniprot ID
P10826
Uniprot Name
Retinoic acid receptor beta
Molecular Weight
50488.63 Da
References
  1. Jones PH, Burnett RD, Fainaru I, Nadolny P, Walker P, Yu Z, Tang-Liu D, Ganesan TS, Talbot DC, Harris AL, Rustin GJ: A phase 1 study of tazarotene in adults with advanced cancer. Br J Cancer. 2003 Sep 1;89(5):808-15. [PubMed:12942109]
  2. Orlandi A, Bianchi L, Costanzo A, Campione E, Giusto Spagnoli L, Chimenti S: Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene. J Invest Dermatol. 2004 Apr;122(4):1037-41. [PubMed:15102095]
  3. Chandraratna RA: Tazarotene--first of a new generation of receptor-selective retinoids. Br J Dermatol. 1996 Oct;135 Suppl 49:18-25. [PubMed:9035701]
  4. Arechalde A, Saurat JH: Management of psoriasis: the position of retinoid drugs. BioDrugs. 2000 May;13(5):327-33. [PubMed:18034539]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Attar M, Dong D, Ling KH, Tang-Liu DD: Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab Dispos. 2003 Apr;31(4):476-81. doi: 10.1124/dmd.31.4.476. [PubMed:12642475]

Drug created on June 13, 2005 07:24 / Updated on September 22, 2020 02:11

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates